Related Experiment Videos
Topiramate for intractable childhood epilepsy
E C Moreland1, D A Griesemer, K R Holden
1Division of Pediatric Neurology, Medical University of South Carolina, Charleston, USA.
Seizure
|March 26, 1999
Summary
Topiramate effectively controlled complex partial seizures in children, with optimal results at specific dosages. While some experienced side effects, others showed improved alertness, necessitating careful cognitive monitoring.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Intractable seizures in children pose significant treatment challenges.
- Topiramate is a novel anticonvulsant with potential therapeutic applications.
Purpose of the Study:
- To evaluate the efficacy and tolerability of topiramate in pediatric patients with intractable seizures.
- To determine optimal dosing and identify potential adverse effects.
Main Methods:
- A cohort of 49 children with intractable seizures was monitored during topiramate therapy.
- Seizure control, efficacy at different doses, and adverse events were assessed.
Main Results:
- Topiramate demonstrated greater efficacy in children with complex partial seizures (80%) compared to generalized seizures (20%).
- Optimal efficacy was observed with topiramate doses ranging from 2.5 to 7.5 mg/kg/day.
- Over half of the children experienced adverse effects potentially impacting learning, while 20% showed improved alertness or behavior.
Conclusions:
- Topiramate is an effective treatment option for pediatric complex partial seizures.
- Careful monitoring of cognitive function is essential during topiramate therapy in children.
- Topiramate may be considered in the treatment pathway for pediatric intractable epilepsy.